Table 3.

Outcomes of series using ureteroscopic treatment for UTUC

Study	Number of patients	mean/median FU (months)	Recurrence (%)	OS (%)	CSS (%)	KPR (%)
			LR / IVR
Hoffman et al 2014 [39]	25	26	36/44	100	100	100
Fajkovic et al., 2013 [5]	20	20	25 / 15	45	95	100
Cutress et al., 2012 [40]	73	54	68 / 53	60	90	81
Grasso et al., 2012 [41]	66	51.5	77 / 61	74	87	83
Gadzinski et al., 2010 [42]	34	58	84 / NR	75	100	89
Cornu et al., 2010 [43]	35	24	60 / 40	100	100	89
Pak et al., 2009 [44]	57	53	90 / NR	93	95	81
Lucas et al., 2008 [45]	39	33	46 / NR	62	82	72
Painter et al., 2008 [46]	45	NR	NR / NR	NR	89	91
Krambeck et al., 2007 [47]	37	32	62 / 37	35	70	70
Reisiger et al., 2007 [48]	10	73	50 / 70	100	100	90
Roupret et al., 2006 [49]	27	52	15 / 22	77	81	74
Johnson et al., 2005 [50]	35	32	68 / NR	NR	100	97
Iborra et al., 2003 [51]	23	NR	35 / NR	NR	96	91
Matsuoka et al., 2003 [52]	26	33	26 / 15	NR	89	NR
Daneshmand et al., 2003 [53]	30	31	90 / 23	77	97	87
Chen et al., 2001 [54]	23	30	64 / 12	NR	NR	NR
Engelmyer et al., 1996 [55]	10	43	70 / NR	90	100	100
Gaboardi et al., 1994 [56]	18	15	50 / NR	100	100	94
Andersen et al., 1994 [2]	10	25	NR / NR	NR	NR	80
Schmeller et al., 1989 [57]	16	14	19 / NR	100	100	100

Abbreviations: CSS, cancer-specific survival; IVR, intravesical recurrence; NR, not reported; OS, overall survival; RNU, radical nephroureterectomy; LR, local recurrence; KPR, kidney preserving rate.